Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...

Under the proposal, only those who are considered obese — someone who has a body mass index of 30 or higher — would qualify ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...